Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan

References

• Landewé RB. American College of Rheumatology recommen-dations for the treatment of RA: an issue of choices. Nat Clin Pract Rheumatol. 2009;5:8–9.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: rec-ommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: an Ameri-can College of Rheumatology/European League Against Rheu-matism collaborative initiative. Arthritis Rheum. 2010;62: 2569–81.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: an Ameri-can College of Rheumatology/European League Against Rheu-matism collaborative initiative. Ann Rheum Dis. 2010;69: 1580–8.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66:1227–32.
   Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial. Arthritis Rheum. 2005;52:3381–90.
   Google Scholar
• Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Ya-mamoto K, Kawai S, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2009;19:273–82.
   Google Scholar
• Nakajima M, Ueda N, Ohara H, Abe M, Kinoshita M. A com-parative study of the effects of bucillamine and salazosulfapyri-dine in the treatment of rheumatoid arthritis. Mod Rheumatol. 2009;19:384–9.
   Google Scholar
• Sagawa A, Fujisaku A, Ohnishi K, Mukai M, Yasuda I, Amasaki Y, et al. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study). Mod Rheumatol. 2011;21:251–7.
   PubMed Web of Science ®Google Scholar
• Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol. 2011;21:458–68.
   Google Scholar
• Lee YH, Woo JH, Choi SJ, Ji JD, Bae SC, Song GG. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol. 2010;39:271–8.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Ducoulombier V, Solau E, Coquerelle P, Houvenagel E, Siame JL, Desprez X, et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine. 2007;74:56–9.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DA528-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol. 2009;19:488–92.
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, Callegari P. Treatment persis-tence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30:1375–84.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17: 283–9.
   Google Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
   PubMedGoogle Scholar
• Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatol-ogists in the 3E initiative. Ann Rheum Dis. 2009;68: 1086–93.
   Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328–46.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Shinozawa T, Yoshida T, Kameda H, Suzuki Y, Kawai S, et al. Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis. Ryumachi. 1995;35:663-70 (in Japanese).
   Google Scholar
• Nagaoka S, Nakamura M, Senuma A, Sekiguchi A. A clinical trial of low dose methotrexate therapy in patients with rheuma-toid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 2005;28: 389–97 (in Japanese).
   Google Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007; 66:1356–62.
   PubMed Web of Science ®Google Scholar
• Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol. 2000;27:1139–47.
   Google Scholar
• Endresen GK, Husby G. Folate supplementation during metho-trexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. Scand J Rheumatol. 2001;30:129–34.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.
   PubMed Web of Science ®Google Scholar
• Attar SM. Adverse effects of low dose methotrexate in rheuma-toid arthritis patients. A hospital-based study. Saudi Med J. 2010;30:909–15.
   Google Scholar